Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:
  • Terminated  
  • Page 1 ·  Next »

NCT ID: NCT03151226 Terminated - Clinical trials for Respiratory Depression

OSA Screen Negative With Spinal Duramorph

Start date: August 2015
Phase: N/A
Study type: Interventional

Non emergent scheduled cesarean sections will be consented to participate in this study of patients who have screened negative for obstructive sleep apnea and who are also BMI>/= 35 to have capnography monitoring postoperatively. The capnography and pulse oximetry will be initiated in the post anesthesia care unit and be worn for 12-24 hours after delivery. Data will be retrieved after that time period in a deidentified fashion. Medication usage will be reviewed as well as the standard of care information from the duramorph monitoring will be retrieved.

NCT ID: NCT03101540 Terminated - Clinical trials for Major Depressive Disorder in Pregnancy

Cytokines, PUFA Tissue Concentrations and Treatment Selection in Antenatal MDD

Start date: August 2011
Phase: Early Phase 1
Study type: Interventional

For a number of reasons women with major depressive disorder often discontinue conventional antidepressants when they become pregnant and prefer not to take them when depressive illness develops in the course of pregnancy. There is now considerable evidence that the administration of the omega-3 polyunsaturated fatty acid, eicosapentaenoic acid (EPA), as monotherapy has antidepressant effects. If it could be clearly established as effective such an approach would offer a valuable alternative for woman who are at risk for, or who develop, depressive disorder during pregnancy. Strongly positive placebo-controlled trials of EPA supplementation, though, co-exist with entirely negative ones. No clear reasons for these discrepancies have emerged but one possibility is that the samples studied have differed in the proportion of individuals likely to benefit from EPA supplementation. As there has been no effort to identify such individuals we propose to explore two groups of measures, both relevant to EPA's likely mechanisms of action, as potential tools for identifying individuals likely to benefit this treatment. Hypothesis: Among women who experience major depressive episodes during their first two trimesters of pregnancy, baseline measures of cytokine activity and erythrocyte PUFA concentrations will be associated, in an additive or interactive fashion, with subsequent improvement in depressive symptoms among women taking omega-3 PUFA supplementation.

NCT ID: NCT03101527 Terminated - Clinical trials for Major Depressive Disorder in Pregnancy

Open Trial Determining Antidepressant Effects of Omega-3 Supplementation During Pregnancy

Start date: May 2011
Phase: Early Phase 1
Study type: Interventional

The purpose of this study is to determine if omega-3 polyunsaturated fatty acids as a monotherapy have antidepressant effects during pregnancy. It will also provide pilot data pertaining to relationships between apparent response to omega-3 monotherapy and both plasma cytokine and erythrocyte essential fatty acid concentrations.

NCT ID: NCT02885285 Terminated - Parkinson's Disease Clinical Trials

The Impact of Three Distinct Exercise Types on Fatigue, Anxiety, and Depression in Parkinson's Disease

PD&Exercise
Start date: August 2016
Phase: N/A
Study type: Interventional

The purpose of the study is to learn about the impact of exercise on fatigue, anxiety, and depression in Parkinson's disease. It is well established that exercise improves the motor symptoms of Parkinson's disease. However, it is not clear which types of exercise are most beneficial for specific non-motor symptoms.

NCT ID: NCT02857088 Terminated - Depression Clinical Trials

Olfactory and Visual Perception in Depressed Patients

PERODEP
Start date: February 2014
Phase: N/A
Study type: Interventional

The study aimed to determine the emotional reactivity of depressed patients to visual and olfactory stimuli in comparison with healthy volunteers.

NCT ID: NCT02856477 Terminated - Depression Clinical Trials

Pharmacogenetic and Antidepressant Treatment in Elderly

Pharmacogeneti
Start date: November 2007
Phase: N/A
Study type: Interventional

The study aims to assess the therapeutic benefits of the adaptation of the antidepressant dose to the metabolic capacity (cytochrome P450 2D6) of elderly depressed patients. Therapeutic benefits are evaluated through the enhancement of efficiency, decrease of the action time and the after effects.

NCT ID: NCT02760927 Terminated - Respiratory Failure Clinical Trials

Assessment of a Oral Endotracheal Tube Fastener on Patients Intubated With Oral Endotracheal Tubes

Start date: March 2016
Phase: N/A
Study type: Interventional

Assessment of AnchorFast Guard Oral Endotracheal Tube Fastener on Patients Intubated with Oral Endotracheal Tubes with Subglottic Suction

NCT ID: NCT02740244 Terminated - Bipolar Depression Clinical Trials

Effect of Intermittent ThetaBurst Stimulation in Treatment-resistant Bipolar Depression

iTBS-BIP
Start date: January 2011
Phase: N/A
Study type: Interventional

The aim is to evaluate the evaluate the clinical interest and the safety of repetitive transcranial magnetic stimulation (rTMS) delivered as intermittent Theta burst stimulation(iTBS) on severity of depression in patients with treatment-resistant bipolar disorder.

NCT ID: NCT02669043 Terminated - Depression Clinical Trials

Physiological and Cognitive Biomarkers for Ketamine's Antidepressant Effects

Start date: July 2016
Phase: N/A
Study type: Interventional

Anxious depression is a particularly difficult-to-treat subtype of depression. Patients with anxious depression do not respond as well to currently available antidepressant medications. Nevertheless, in previous studies, low dose IV ketamine, which rapidly decreases symptoms of depression within hours in many patients with "treatment-resistant" depression, has been associated with superior efficacy in those individuals with anxious compared with non-anxious depression. In order to understand this unique effect more fully, the current protocol is aimed at further delineating biomarkers of ketamine's effects among individuals with treatment-resistant anxious depression compared to those with nonanxious depression.

NCT ID: NCT02582528 Terminated - Depression Clinical Trials

Cognitive Remediation in Youth at Risk of Serious Mental Illness

Start date: February 2016
Phase: N/A
Study type: Interventional

The primary aim of the project is to test the effectiveness of a cognitive remediation treatment (CRT) program, My Brain Solutions (MBS), in addition to motivational interviewing (MI) in improving cognition and functional outcome of individuals at risk of SMI. An active control treatment consisting of CRT alone will be used. Hypotheses: 1. Both study groups will have improvement in cognition at the end of treatment; 2. CRT+MI group will have increased treatment adherence and superior improvements in cognition at the end of treatment and 12 months post baseline compared to the CRT only group; Secondary Hypothesis: 3. Improved cognition will be associated with improved functional outcome.